Browsing by Author "Neha Kanojia"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Modified Excipients in Novel Drug Delivery: Need of the Day
    (Chitkara University Publications, 2013-05) Neha Kanojia; Loveleen Kaur; Manju Nagpal; Rajni Bala
    Drug products not only contain “actives” that confer the intended therapeutic benefits such as pain relief or act on particular part of the body, but contain other materials that are also “functional” with respect to the drug product. These are known as excipients and specific functionality which they confer to a particular product is independent upon the process used to add the excipient to the formulation and its exact location within the final dosage form. Introduction of novel drug delivery systems and new drug moieties lead to the need for new excipients with varied characteristics. Development of new excipient entities and their evaluation is a costly procedure; modification of existing excipients is very easy, more economical and less time consuming. The development of excipients that are capable of fulfilling multifunctional roles such as enhancing drug bioavailability and drug stability as well as controlling the release of the drug according to the therapeutic needs is one of the most important prerequisites for further progress in the design of novel drug delivery systems. The main focus of this article is on synthetic novel excipients that perform multiple functions in pharmaceutical formulations.
  • No Thumbnail Available
    Item
    Transferosomes: A Promising Drug Delivery Tool in Neurodegenerative Disorders
    (Chitkara University Publications, 2024-11-20) Neha Kanojia; Jatin Kumar; Aruna Sharma; Amit Chaudhary
    Background: Globally, neurodegenerative diseases (NDs) are complicated, progressive, and frequently lethal conditions that greatly increase mortality and disability. Because there are currently no effective treatments for conditions including Parkinson’s disease, Alzheimer’s disease, and numerous psychiatric diseases (such as depression, anxiety, bipolar disorder, and schizophrenia), these conditions continue to present significant healthcare issues. The blood-brain barrier (BBB), a highly selective membrane that prevents therapeutic medicines from entering the central nervous system (CNS), is a crucial obstacle in the development of effective treatments. Due to the poor brain bioavailability of conventional drug delivery systems, novel approaches are required to improve medication penetration and efficacy. Purpose: This review examines the possibilities of nanocarrier-based systems, especially transferosomes; this review seeks to solve the shortcomings of traditional drug delivery techniques in the treatment of NDs. These ultra-deformable vesicles have demonstrated potential in overcoming BBB restrictions, boosting the distribution of neuroprotective medications to the brain, and enhancing therapeutic results. Methods: The review summarizes the results of current studies on medication delivery systems based on transferosomes in relation to mental and neurodegenerative diseases. It reviews preclinical research on animal models, emphasizing enhancements in cognitive performance, locomotor activity, cerebral bioavailability, and biochemical indicators, including neurotransmitter levels and oxidative stress. Conclusion: A promising development in medicine delivery for NDs driven by nanotechnology is transferosomes. They are a strong contender to replace conventional drug delivery techniques because of their capacity to increase brain bioavailability, reduce systemic side effects, and boost therapeutic efficacy. Preclinical research suggests that this relatively new method has great promise for treating a range of mental and neurodegenerative diseases. To prove transferosomes as a practical method for enhancing CNS medication distribution and patient outcomes, future studies should concentrate on refining formulations, carrying out comprehensive clinical trials, and resolving regulatory issues.